Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally twice daily. Doses may be adjusted based on symptom severity and gastric acid output. Doses up to 240 mg daily have been administered.
## Pediatric Dosing
* **12 to 17 years:**
* **Erosive esophagitis:** 40 mg orally once daily for up to 4 weeks.
* **GERD (symptomatic):** 20 mg orally once daily for up to 8 weeks.
* **5 to 11 years:**
* **Erosive esophagitis:** 20 mg orally once daily for up to 4 weeks.
* *Dosing for children younger than 5 years is not established.*
## Dose Adjustments
* No dose adjustment is typically required for hepatic or renal impairment. However, caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, headache, nausea, dizziness, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, vitamin B12 deficiency, hypomagnesemia (potentially severe), fundic gland polyps.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, mycophenolate mofetil. Concomitant use may decrease absorption of these drugs.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution and potential dose adjustment of substrates like clopidogrel may be warranted.
## Monitoring
* Monitor for symptoms of *C. difficile*-associated diarrhea.
* Consider monitoring serum magnesium levels with prolonged therapy (e.g., >1 year) or concomitant diuretic use.
* Assess for signs and symptoms of bone fracture risk factors with long-term use.
* Monitor for signs of vitamin B12 deficiency.
## Clinical Pearls
* Administer pantoprazole oral suspension at least 30 minutes before a meal.
* Pantoprazole delayed-release tablets should be swallowed whole and not chewed or crushed.
* Long-term PPI use is associated with increased risk of osteoporosis-related fractures, *C. difficile* infection, vitamin B12 deficiency, and hypomagnesemia. Use the lowest effective dose for the shortest duration needed.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for complete details.*
